<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00380354</url>
  </required_header>
  <id_info>
    <org_study_id>IPA101985</org_study_id>
    <nct_id>NCT00380354</nct_id>
  </id_info>
  <brief_title>Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma</brief_title>
  <official_title>A Two-centre, Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With Repeat Doses of Inhaled GSK256066 on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of GSK256066 in the treatment of subjects&#xD;
      with mild bronchial asthma, using a number of clinical and biological markers of efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthmatic response</measure>
    <time_frame>after 7 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 Concentration of exhaled nitric oxide</measure>
    <time_frame>on day 8 of each treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Asthma</condition>
  <condition>Mild Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK256066</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Documented history of bronchial asthma, first diagnosed at least 6 months prior to the&#xD;
             screening visit and currently being treated only with intermittent short-acting beta&#xD;
             -agonist therapy by inhalation.&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 &gt;75% of predicted at screening.&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Demonstration of a positive reaction to at least one allergen from a battery of&#xD;
             allergens (including house dust mite, grass pollen and cat hair on skin prick testing&#xD;
             at screening, or within 12 months of study start.&#xD;
&#xD;
          -  Have Asthmatic response&#xD;
&#xD;
          -  Able and willing to give written informed consent to take part in the study.&#xD;
&#xD;
          -  Available to complete all study measurements.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of cardiovascular disease&#xD;
&#xD;
          -  Clinically significant abnormalities in safety laboratory analysis at screening&#xD;
             including any subject who has greater than &quot;trace urine protein levels&quot; following&#xD;
             urinalysis at screening.&#xD;
&#xD;
          -  History of hayfever&#xD;
&#xD;
          -  The subject has tested positive for hepatitis C antibody or hepatitis B surface&#xD;
             antigen.&#xD;
&#xD;
          -  The subject has tested positive for HIV antibodies.&#xD;
&#xD;
          -  The subject has positive drugs of abuse test.&#xD;
&#xD;
          -  Subjects weighing less than 50kg are to be excluded from participating in the study.&#xD;
&#xD;
          -  The subject has participated in a study with a new molecular entity during the&#xD;
             previous 3 months.&#xD;
&#xD;
          -  History of being unable to tolerate or complete methacholine, and/or allergen&#xD;
             challenge tests.&#xD;
&#xD;
          -  There is a risk of non-compliance with study medication or study procedures.&#xD;
&#xD;
          -  History of blood donation (450 mL) within 2 months of starting the clinical study.&#xD;
&#xD;
          -  The subject regularly drinks more than 28 units of alcohol in a week if male, or 21&#xD;
             units per week if female. One unit of alcohol is defined as a medium (125 ml) glass of&#xD;
             wine, half a pint (250 ml) of beer or one measure (24 ml) of spirits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2006</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergen</keyword>
  <keyword>methacholine</keyword>
  <keyword>GSK256066</keyword>
  <keyword>mild asthmatics</keyword>
  <keyword>repeat dose</keyword>
  <keyword>challenge</keyword>
  <keyword>late asthmatic response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 17, 2017</submitted>
    <returned>March 16, 2018</returned>
    <submitted>March 26, 2018</submitted>
    <submission_canceled>August 15, 2018</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

